Evidence map›Paper›PMID 33665204›Full record

ArticleFrontiers in molecular biosciences2020

Serum IRAP, a Novel Direct Biomarker of Prediabetes and Type 2 Diabetes?

Candice Trocmé, Nicolas Gonnet, Margaux Di Tommaso, Hanen Samouda, Jean-Luc Cracowski, Claire Cracowski, Stéphanie Lambert-Porcheron, Martine Laville, Estelle Nobécourt, Chiraz Gaddhab and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01648478 (Evaluation of Plasma IRAP Secreted Protein as a New Insulin Sensitivity Biomarker, Using Hyperinsulinemic Euglycemic Clamp), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01648478 nacompletednot on this map

Evaluation of Plasma IRAP Secreted Protein as a New Insulin Sensitivity Biomarker, Using Hyperinsulinemic Euglycemic Clamp

TypeinterventionalSponsorHospices Civils de LyonRan2012 to 2012Enrolled21ConditionsInsulin ResistanceArmsIt is a hyperinsulinemic-euglycemic clamp.
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 3 countries.

Candice TrocméDepartment of Biochemistry, Molecular Biology and Environmental Toxicology, Centre Hospitalier Grenoble-Alpes, La Tronche, France.
Nicolas GonnetCentre d'Investigation Clinique, Centre Hospitalier Grenoble-Alpes, La Tronche, France.
Margaux Di TommasoPopulation Health Department, Nutrition and Health Research Group, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Hanen SamoudaPopulation Health Department, Nutrition and Health Research Group, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Jean-Luc CracowskiCentre d'Investigation Clinique, Centre Hospitalier Grenoble-Alpes, La Tronche, France.
Claire CracowskiCentre d'Investigation Clinique, Centre Hospitalier Grenoble-Alpes, La Tronche, France.
Stéphanie Lambert-PorcheronCentre de Recherche en Nutrition Humaine Rhône-Alpes, Pierre-Bénite, France.
Martine LavilleCentre de Recherche en Nutrition Humaine Rhône-Alpes, Pierre-Bénite, France.
Estelle NobécourtDepartment of Endocrinology, Metabolic Diseases and Nutrition, Centre Hospitalier Universitaire de La Réunion, Saint-Denis, France.
Chiraz GaddhabDepartment of Pediatrics, Diabetes and Endocrinology Care, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
Allan Le LayCHU Grenoble-Alpes, Department of Biochemistry, Molecular Biology and Environmental Toxicology, Grenoble, France.
Torsten BohnPopulation Health Department, Nutrition and Health Research Group, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Christine PoitouINSERM UMR-S 1269, NutriOmics, Paris, France.
Karine ClémentINSERM UMR-S 1269, NutriOmics, Paris, France.
Fahd Al-MullaDepartment of Genomics and Bioinformatics, Dasman Diabetes Institute, Kuwait City, Kuwait.
Milad S BitarDepartment of Genomics and Bioinformatics, Dasman Diabetes Institute, Kuwait City, Kuwait.
Serge P BottariPopulation Health Department, Nutrition and Health Research Group, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Centre Hospitalier Universitaire de Grenoble · FRLuxembourg Institute of Health · LUDasman Diabetes Institute · KWInserm · FRCentre Hospitalier de Luxembourg · LUCentre Hospitalier Universitaire de La Réunion · FRHôpital Lyon Sud · FRNutrition et obésité : approches systémiques · FRSorbonne Université · FRUniversité Grenoble Alpes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance (IR), currently called prediabetes (PD), affects more than half of the adult population worldwide. Type 2 diabetes (T2D), which often follows in the absence of treatment, affects more than 475 million people and represents 10-20% of the health budget in industrialized countries. A preventive public health policy is urgently needed in order to stop this constantly progressing epidemic. Indeed, early management of prediabetes does not only strongly reduce its evolution toward T2D but also strongly reduces the appearance of cardiovascular comorbidity as well as that of associated cancers. There is however currently no simple and reliable test available for the diagnosis or screening of prediabetes and it is generally estimated that 20-60% of diabetics are not diagnosed. We therefore developed an ELISA for the quantitative determination of serum Insulin-Regulated AminoPeptidase (IRAP). IRAP is associated with and translocated in a stoechiometric fashion to the plasma membrane together with GLUT4 in response to insulin in skeletal muscle and adipose tissue which are the two major glucose storage sites. Its extracellular domain (IRAPs) is subsequently cleaved and secreted in the blood stream. In T2D, IRAP translocation in response to insulin is strongly decreased. Our patented sandwich ELISA is highly sensitive (≥10.000-fold "normal" fasting concentrations) and specific, robust and very cost-effective. Dispersion of fasting plasma concentration values in a healthy population is very low (101.4 ± 15.9 μg/ml) as compared to those of insulin (21-181 pmol/l) and C-peptide (0.4-1.7 nmol/l). Results of pilot studies indicate a clear correlation between IRAPs levels and insulin sensitivity. We therefore think that plasma IRAPs may be a direct marker of insulin sensitivity and that the quantitative determination of its plasma levels should allow large-scale screening of populations at risk for PD and T2D, thereby allow the enforcement of a preventive health policy aiming at efficiently reducing this epidemic.

Indexed as

biomarkerdiabetesdiagnosisGLUT4IRAPprediabetesscreening

Identifiers

PMID33665204
PMCPMC7921167
OpenAlexW3132840388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.